Coronary Obstruction From TAVR in Native Aortic Stenosis: Development and Validation of Multivariate Prediction Model.


Journal

JACC. Cardiovascular interventions
ISSN: 1876-7605
Titre abrégé: JACC Cardiovasc Interv
Pays: United States
ID NLM: 101467004

Informations de publication

Date de publication:
27 02 2023
Historique:
received: 14 09 2022
revised: 15 11 2022
accepted: 17 11 2022
pmc-release: 27 02 2024
entrez: 1 3 2023
pubmed: 2 3 2023
medline: 4 3 2023
Statut: ppublish

Résumé

Transcatheter aortic valve replacement (TAVR)-related coronary artery obstruction prediction remains unsatisfactory despite high mortality and novel preventive therapies. This study sought to develop a predictive model for TAVR-related coronary obstruction in native aortic stenosis. Preprocedure computed tomography and fluoroscopy images of patients in whom TAVR caused coronary artery obstruction were collected. Central laboratories made measurements, which were compared with unobstructed patients from a single-center database. A multivariate model was developed and validated against a 1:1 propensity-matched subselection of the unobstructed cohort. Sixty patients with angiographically confirmed coronary obstruction and 1,381 without obstruction were included. In-hospital death was higher in the obstruction cohort (26.7% vs 0.7%; P < 0.001). Annular area and perimeter, coronary height, sinus width, and sinotubular junction height and width were all significantly smaller in the obstructed cohort. Obstruction was most common on the left side (78.3%) and at the level of the coronary artery ostium (92.1%). Coronary artery height and sinus width, but not annulus area, were significant risk factors for obstruction by logistic regression but performed poorly in predicting obstruction. The new multivariate model (coronary obstruction IF cusp height > coronary height, AND virtual valve-to-coronary distance ≤4 mm OR culprit leaflet calcium volume >600 mm A novel computed tomography-based multivariate prediction model that can be implemented routinely in real-world practice predicted coronary artery obstruction from TAVR in native aortic stenosis.

Sections du résumé

BACKGROUND
Transcatheter aortic valve replacement (TAVR)-related coronary artery obstruction prediction remains unsatisfactory despite high mortality and novel preventive therapies.
OBJECTIVES
This study sought to develop a predictive model for TAVR-related coronary obstruction in native aortic stenosis.
METHODS
Preprocedure computed tomography and fluoroscopy images of patients in whom TAVR caused coronary artery obstruction were collected. Central laboratories made measurements, which were compared with unobstructed patients from a single-center database. A multivariate model was developed and validated against a 1:1 propensity-matched subselection of the unobstructed cohort.
RESULTS
Sixty patients with angiographically confirmed coronary obstruction and 1,381 without obstruction were included. In-hospital death was higher in the obstruction cohort (26.7% vs 0.7%; P < 0.001). Annular area and perimeter, coronary height, sinus width, and sinotubular junction height and width were all significantly smaller in the obstructed cohort. Obstruction was most common on the left side (78.3%) and at the level of the coronary artery ostium (92.1%). Coronary artery height and sinus width, but not annulus area, were significant risk factors for obstruction by logistic regression but performed poorly in predicting obstruction. The new multivariate model (coronary obstruction IF cusp height > coronary height, AND virtual valve-to-coronary distance ≤4 mm OR culprit leaflet calcium volume >600 mm
CONCLUSIONS
A novel computed tomography-based multivariate prediction model that can be implemented routinely in real-world practice predicted coronary artery obstruction from TAVR in native aortic stenosis.

Identifiants

pubmed: 36858660
pii: S1936-8798(22)02219-1
doi: 10.1016/j.jcin.2022.11.018
pmc: PMC9991077
mid: NIHMS1859160
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

415-425

Subventions

Organisme : Intramural NIH HHS
ID : Z99 HL999999
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 American College of Cardiology Foundation. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures This work was supported by a research grant from Medtronic to MedStar Cardiovascular Research Network and MedStar Health. Dr Kamioka has served as a proctor for Edwards Lifesciences. Dr Ludwig has received grant support from the German Heart Foundation; and received travel compensation from Edwards Lifesciences. Dr. Sinning has received speaker honoraria and research grants from Abbott, Abiomed, Medtronic, Boston Scientific, and Edwards Lifesciences; and served as a proctor for Medtronic and Boston Scientific. Dr Fuku has served as a proctor for Edwards Lifesciences and Medtronic. Dr Iyer has served as a proctor for Edwards Lifesciences, Medtronic, and Boston Scientific. Dr Rodriguez has served as a speaker for Medtronic, Abbott, and Edwards Lifesciences. Dr Montorfano has served as a proctor for Edwards Lifesciences, Boston Scientific, and Abbott. Dr Ancona has received consulting fees from Abbott and Abiomed. Dr Ahmad has served as a proctor for Edwards Lifesciences. Dr Ruggiero has served as a proctor for Abbott and Edwards Lifesciences; served as a consultant for Abbott, Edwards Lifesciences, and RegenX-Bio; and received research support from Ancora Heart and Bard. Dr Weissman has served as the director of an academic cardiac computed tomography core lab with institutional contracts with Ancora Heart and LivaNova. Dr Waksman has served on the advisory board for Abbott Vascular, Boston Scientific, Medtronic, Philips IGT, and Pi-Cardia Ltd; has served as a consultant for Abbott Vascular, Biotronik, Boston Scientific, Cordis, Medtronic, Philips IGT, Pi-Cardia Ltd, Swiss Interventional Systems/SIS Medical AG, Transmural Systems Inc, and Venous MedTech; has received institutional grant support from Amgen, Biotronik, Boston Scientific, Chiesi, Medtronic, and Philips IGT; and is an investor in MedAlliance and Transmural Systems Inc. Dr Rogers has served as a proctor and consultant for Boston Scientific, Edwards Lifesciences, and Medtronic; has served on the advisory board for Medtronic; and holds equity interest in Transmural Systems Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Références

Clin Res Cardiol. 2021 Dec;110(12):1900-1911
pubmed: 34156524
Eur Heart J. 2018 Feb 21;39(8):687-695
pubmed: 29020413
JACC Cardiovasc Interv. 2019 Jul 8;12(13):1240-1252
pubmed: 31202947
Circulation. 2015 Jan 13;131(2):211-9
pubmed: 25561516
J Am Coll Cardiol. 2018 Apr 10;71(14):1513-1524
pubmed: 29622157
JACC Cardiovasc Interv. 2021 May 10;14(9):941-948
pubmed: 33958168
JACC Cardiovasc Interv. 2020 Mar 23;13(6):751-761
pubmed: 32192695
J Am Coll Cardiol. 2013 Oct 22;62(17):1552-62
pubmed: 23954337

Auteurs

Jaffar M Khan (JM)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA; Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.

Norihiko Kamioka (N)

Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia, USA; Department of Cardiology, Tokai University School of Medicine, Isehara, Japan.

John C Lisko (JC)

Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia, USA.

Emily Perdoncin (E)

Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia, USA.

Cheng Zhang (C)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.

Aneel Maini (A)

Georgetown University School of Medicine, Washington, DC, USA.

Mao Chen (M)

Department of Cardiology, West China School of Medicine, West China Hospital, Sichuan University, China.

Yijian Li (Y)

Department of Cardiology, West China School of Medicine, West China Hospital, Sichuan University, China.

Sebastian Ludwig (S)

Department of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany; Cardiovascular Research Foundation, New York, New York, USA.

Dirk Westermann (D)

Department of Cardiology and Angiology I, University Heart Center Freiburg - Bad Krozingen, Medical Faculty, University of Freiburg, Freiburg, Germany.

Ignacio J Amat Santos (IJ)

Department of Cardiology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.

Łukasz Kalińczuk (Ł)

National Institute of Cardiology, Warsaw, Poland.

Jan-Malte Sinning (JM)

Heart Center Bonn, University of Bonn, Bonn Germany.

Tomohiro Kawaguchi (T)

Department of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan.

Yasushi Fuku (Y)

Department of Cardiology, Kurashiki Central Hospital, Kurashiki, Japan.

Asim N Cheema (AN)

Department of Interventional Cardiology, St. Michael's Hospital, Toronto, Ontario, Canada.

Afonso Félix-Oliveira (A)

Department of Cardiology, Hospital de Santa Cruz, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal; Institute of Pharmacology and Neurosciences, Faculty of Medicine, Lisbon University, Lisbon, Portugal.

Masanori Yamamoto (M)

Department of Cardiology, Toyohashi Heart Center/Nagoya Heart Center, Nagoya, Japan.

Ai Kagase (A)

Department of Cardiology, Toyohashi Heart Center/Nagoya Heart Center, Nagoya, Japan.

Pablo Codner (P)

Department of Cardiology, Rabin Medical Center, Petah Tikva, Israel.

Raquel Del Valle (RD)

Interventional Cardiology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.

Vijay S Iyer (VS)

Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.

Hyo-Soo Kim (HS)

Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.

Mao-Shin Lin (MS)

Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan.

Brijeshwar Maini (B)

Department of Cardiology, Florida Atlantic University, Boca Raton, Florida, USA.

Roberto Rodriguez (R)

Structural Heart Program, Main Line Health, Lankenau Medical Center, Wynnewood, Pennsylvania, USA.

Matteo Montorfano (M)

Interventional Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Marco B Ancona (MB)

Interventional Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Norio Tada (N)

Department of Cardiology, Sendai Kosei Hospital, Sendai, Japan.

Masaki Miyasaka (M)

Department of Cardiology, Sendai Kosei Hospital, Sendai, Japan.

Hasan Ahmad (H)

Department of Cardiology, Westchester Medical Center, Valhalla, New York, USA.

Nicholas J Ruggiero (NJ)

Division of Cardiology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.

Rebecca Torguson (R)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.

Itsik Ben-Dor (I)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.

Christian C Shults (CC)

Department of Cardiac Surgery, MedStar Washington Hospital Center, Washington, DC, USA.

Gaby Weissman (G)

Department of Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.

Robert J Lederman (RJ)

Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.

Adam B Greenbaum (AB)

Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia, USA.

Vasilis C Babaliaros (VC)

Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia, USA.

Ron Waksman (R)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.

Toby Rogers (T)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA; Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA. Electronic address: toby.rogers@medstar.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH